Efficacy trials of Lassa Therapeutics: endpoints, trial design, site selection

Overview

WHO convened on April 2018 a group of about 30 experts in epidemiology, regulatory, preclinical and clinical trials, in a workshop on planning for Lassa therapeutics efficacy trials.

The workshop aimed to define generic principles on how to best design, conduct and analyse therapeutics trials against LF, based on the available scientific evidence as well as on lessons learned from the public health response to LF outbreaks.